Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:29am CET

--Judge rules U.S. patent for Vytorin and Zetia is valid and enforceable

--Mylan had challenged patent in bid to sell generic Vytorin and Zetia

--Merck patent due to expire in April 2017

(Adds statement from Merck, additional details.)

 
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said the patent for was valid and enforceable. The patent covers ezetimibe, an active ingredient in both Zetia and Vytorin.

Merck, based in Whitehouse Station, N.J., said the U.S. patent for Vytorin and Zetia is due to expire in April 2017.

"The court appropriately ruled that the patent for Zetia and Vytorin in the U.S. is valid and enforceable," Bruce N. Kuhlik, executive vice president and general counsel of Merck, said in a press release.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell generic versions of Vytorin and Zetia before the patent expired, arguing that the patent was invalid and unenforceable.

Merck filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's plan to sell generic Vytorin, and in 2010 sued to block Mylan from selling generic Zetia. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

Merck said the court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of the patent.

A Mylan spokeswoman couldn't immediately be reached for comment.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
02/28 MERCK : & CO., INC. Management's Discussion and Analysis of Financial Condition ..
02/28 MERCK : Announces Second-Quarter 2017 Dividend
02/28 MERCK : Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased..
02/28 MERCK : recommends dividend of Rs 11 per equity share of Rs 10 each
02/26 MERCK : Letermovir, an Investigational Antiviral Medicine for Prevention of Cyto..
02/24 MERCK : In First Phase 3 Trial, Merck’s Investigational Inactivated Varice..
02/24 MERCK : Study Findings from Merck & Company Broaden Understanding of Hepatitis C..
02/24 RECENT STUDIES FROM MERCK & COMPANY : A...
02/24 MERCK : Announces EPOCH Study of Verubecestat for the Treatment of People with M..
02/24 MERCK : New Data from Merck & Company Illuminate Findings in Immunoglobulins (Tr..
More news
Sector news : Pharmaceuticals - NEC
07:15p Banks, builders boost European shares as Trump-trade back on
04:21p EpiPen maker Mylan forecasts strong 2017; shares jump
12:41p Bayer sells 11 percent of Covestro for 1.46 billion euros
11:18a Banks, basic resources lift European shares on Trump-trade
09:44aDJCovestro Shares Nosedive After Bayer Reduces Stake
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10:57a BRISTOL-MYERS SQUIBB : A High Risk High Return Bet For 2017
02/28 Merck declares $0.47 dividend
02/28 Merck's Idenix Write-Off Another Bad Sign In Hep C
02/27 Idera Pharmaceuticals' Well-Funded And Growing Pipeline Of Potentially Blockb..
02/27 Roche's Renal Success Spells Danger For All-Comer Studies
Advertisement
Financials ($)
Sales 2017 39 712 M
EBIT 2017 13 517 M
Net income 2017 8 459 M
Debt 2017 4 774 M
Yield 2017 2,85%
P/E ratio 2017 20,15
P/E ratio 2018 17,12
EV / Sales 2017 4,69x
EV / Sales 2018 4,54x
Capitalization 181 613 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,7 $
Spread / Average Target 4,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.12.38%181 558
JOHNSON & JOHNSON6.24%332 993
ROCHE HOLDING LTD.4.73%209 283
PFIZER INC.5.48%204 030
NOVARTIS AG5.06%203 039
SANOFI4.59%110 124
More Results